David Fredrickson, Executive Vice-President of Oncology Business at AstraZeneca, shared a post on LinkedIn:
“Last week, I was proud to join Pascal Soriot in meetings with members of the US Administration to sign a historic agreement that delivers on all four of the President’s requests to reduce medicine costs while safeguarding America’s biopharmaceutical innovation and leadership.
The agreement builds on our plans to invest $50 billion in US medicines manufacturing and R&D by 2030 and supports our ambition to reach $80 billion in total revenue by that year, as we continue to deliver for patients.
Looking ahead, I’m encouraged by what science and policy can make possible: faster progress for patients, broader access to innovative therapies, and a stronger US ecosystem that accelerates breakthroughs from the lab to the clinic.
Thank you to the President, Howard W. Lutnick, Secretary Kennedy, Mehmet Oz, Glenn Youngkin, Chris Klomp, and John Brooks, for your partnership in reaching this agreement.”
More posts featuring David Fredrickson.
